Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/159958
Title: Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia.
Author: Ettcheto Arriola, Miren
Olloquequi González, Jordi
Sánchez-López, E. (Elena)
Busquets Figueras, Oriol
Cano Fernández, Amanda
Manzine, Patricia
Beas Zárate, Carlos
Castro Torres, Ruben Dario
García López, María Luisa
Bulló, Mònica
Auladell i Costa, M. Carme
Folch López, Jaume
Camins Espuny, Antoni
Keywords: Benzodiazepines
Malaltia d'Alzheimer
Demència
Cognició
Factors de risc en les malalties
Insomni
Benzodiazepines
Alzheimer's disease
Dementia
Cognition
Risk factors in diseases
Insomnia
Issue Date: 8-Jan-2020
Publisher: Frontiers Media
Abstract: Benzodiazepines (BZDs) and Z-drugs are compounds widely prescribed in medical practice due to their anxiolytic, hypnotic, and muscle relaxant properties. Yet, their chronic use is associated with cases of abuse, dependence, and relapse in many patients. Furthermore, elderly people are susceptible to alterations in pharmacodynamics, pharmacokinetics as well as to drug interaction due to polypharmacy. These situations increase the risk for the appearance of cognitive affectations and the development of pathologies like Alzheimer's disease (AD). In the present work, there is a summary of some clinical studies that have evaluated the effect of BZDs and Z-drugs in the adult population with and without AD, focusing on the relationship between their use and the loss of cognitive function. Additionally, there is an assessment of preclinical studies focused on finding molecular proof on the pathways by which these drugs could be involved in AD pathogenesis. Moreover, available data (1990-2019) on BZD and Z-drug use among elderly patients, with and without AD, was compiled in this work. Finally, the relationship between the use of BZD and Z-drugs for the treatment of insomnia and the appearance of AD biomarkers was analyzed. Results pointed to a vicious circle that would worsen the condition of patients over time. Likewise, it put into relevance the need for close monitoring of those patients using BZDs that also suffer from AD. Consequently, future studies should focus on optimizing strategies for insomnia treatment in the elderly by using other substances like melatonin agonists, which is described to have a much more significant safety profile.
Note: Reproducció del document publicat a: https://doi.org/10.3389/fnagi.2019.00344
It is part of: Frontiers in Aging Neuroscience, 2020, vol. 11, num. 344
URI: http://hdl.handle.net/2445/159958
Related resource: https://doi.org/10.3389/fnagi.2019.00344
ISSN: 1663-4365
Appears in Collections:Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
695769.pdf471.39 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons